Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-109 phase 2 expansion in advanced solid tumors including Ewing sarcoma and colorectal cancer
2023-508139-29-00Phase 2Authorised
- Sponsor
- Inhibrx Biosciences
- Start
- Jun 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, open-label trial of ozekibart in Ewing sarcoma, colorectal adenocarcinoma and advanced nonhematological malignancy (3 cohorts), sponsored by Inhibrx Biosciences. Primary endpoints: Treatment-emergent adverse events, dose-limiting toxicities, and serious adverse events and Objective response rate and duration of response. Planned start Jun 2024; status: authorised.
02
Drugs
ozekibart
03
Conditions
Ewing sarcomacolorectal adenocarcinomaadvanced nonhematological malignancy
Beyond the preview
Go deeper on 2023-508139-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508139-29-00.